Aldosterone induces a vascular inflammatory phenotype in the rat heart

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 283, Issue 5 52-5, 2002, Pages

  Rocha, Ricardo ^a   Rudolph, Amy E ^a   Frierdich, Gregory E ^a   Nachowiak, Denise A ^a   Kekec, Beverly K ^a   Blomme, Eric A G ^a,b   McMahon, Ellen G ^a   Delyani, John A ^a  

^a PFIZER INC   (United States)

^b Division of Global Toxicology   (United States)

Author keywords

Cyclooxygenase 2; Eplerenone; Macrophage chemoattractant protein 1; Osteopontin

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; COMPLEMENTARY RNA; CYCLOOXYGENASE 2; EPLERENONE; INTERCELLULAR ADHESION MOLECULE 1; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOPONTIN; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SPIRONOLACTONE; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE EXPRESSION; HEART MUSCLE FIBROSIS; HISTOPATHOLOGY; HYPERTENSION; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INFLAMMATION; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA PROBE;

EID: 0036838616     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.01096.2001     Document Type: Article

References (35)

1. Ashizaw N., Graf K, Do YS, Nunohiro T, Giachelli CM, Meehan WP, Tuan TL, and Hsueh WA. Osteopontin is produced by rat cardiac fibroblasts and mediates AII-induced DNA synthesis and collagen gel contraction. J Clin Invest 98: 2218-2227, 1996.
2. Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S, Rittling SR, Denhardt DT, Glimcher MJ, and Cantor H. Eta-1 (osteopontin): An early component of type-1 (cell-mediated) immunity. Science 287: 860-864, 2000.
3. Behr TM, Wang X, Aiyar N, Coatney RW, Li X, Koster P, Angermann CE, Ohlstein E, Feuerstein GZ, and Winaver J. Monocyte chemoattractant protein-1 is upregulated in rats with volume-overload congestive heart failure. Circulation 102: 1315-1322, 2000.
4. Belton O, Byrne D, Kearney D, Leahy A, and Fitzgerald DJ. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 102: 840-845, 2000.
5. Brilla CG and Weber KT. Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc Res 26: 671-677, 1992.
6. Delyani JA. Mineralocorticoid receptor antagonists: The evolution of utility and pharmacology. Kidney Int 57: 1408-1411, 2000.
7. Denhardt DT and Noda M. Osteopontin expression and function: role in bone remodeling. J Cell Biochem 30-31, Suppl: 92-102, 1998.
8. Friedman SM and Friedman CL. Observations on the role of the rat kidney in hypertension caused by deoxycorticosterone acetate. J Exp Med 87: 329, 1948.
9. Gadeau AP, Campan M, Millet D, Candresse T, and Desgranges C. Osteopontin overexpression is associated with arterial smooth muscle cell proliferation in vitro. Arterioscler Thromb 13: 120-125, 1993.
10. Gavras H, Brunner HR, Laragh JH, Vaughan ED Jr, Koss M, Cote LJ, and Gavras I. Malignant hypertension resulting from deoxycorticosterone acetate and salt excess. Role of renin and sodium in vascular changes. Circ Res 36: 300-309, 1975.
11. Giachelli CM, Liaw L, Murry CE, Schwartz SM, and Almeida M. Osteopontin expression in cardiovascular diseases. Ann NY Acad Sci 760: 109-126, 1995.
12. Graf K, Do YS, Ashizawa N, Meehan WP, Giachelli CM, Marboe CC, Fleck E, and Hsueh WA. Myocardial osteopontin expression is associated with left ventricular hypertrophy. Circulation 96: 3063-3071, 1997.
13. Jiang Y, Beller DI, Frendl G, and Greaves DT. Monocyte chemoattractant protein-1 regulates adhesion molecule expression and cytokine production in human monocytes. J Immunol 148: 2423-2428, 1992.
14. Koyanagi M, Egashira K, Kitamoto S, Ni W, Shimokawa H, Takeya M, Yoshimura T, and Takeshita A. Role of monocyte chemoattractant protein-1 in cardiovascular remodeling induced by chronic blockade of nitric oxide synthesis. Circulation 102: 2243-2248, 2000.
15. Lehmann MH, Kuhnert H, Muller S, and Sigusch HH. Monocyte chemoattractant protein 1 (MCP-1) gene expression in dilated cardiomyopathy. Cytokine 10: 739-746, 1998.
16. Ley K. Molecular mechanisms of leukocyte recruitment in the inflammatory process. Cardiovasc Res 32: 733-742, 1996.
17. Liaw L, Almeida M, Hart CE, Schwartz SM, and Giachelli CM. Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro. Circ Res 74: 214-224, 1994.
18. Lombes M, Alfaidy N, Eugene E, Lessana A, Farman N, and Bonvalet JP. Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 β-hydroxysteroid dehydrogenase in the human heart. Circulation 92: 175-182, 1995.
19. Mervaala EM, Muller DN, Park JK, Schmidt F, Lohn M, Breu V, Dragun D, Ganten D, Haller H, and Luft FC. Monocyte infiltration and adhesion molecules in a rat model of high human renin hypertension. Hypertension 33: 389-395, 1999.
20. O'Regan AW, Hayden JM, and Berman JS. Osteopontin augments CD3-mediated interferon-γ and CD40 ligand expression by T cells, which results in IL-12 production from peripheral blood mononuclear cells. J Leukoc Biol 68: 495-502, 2000.
21. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, and Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341: 709-717, 1999.
22. Robert V, Silvestre JS, Charlemagne D, Sabri A, Trouve P, Wassef M, Swynghedauw B, and Delcayre C. Biological determinants of aldosterone-induced cardiac fibrosis in rats. Hypertension 26: 971-978, 1995.
23. Rocha R, Chander PN, Khanna K, Zuckerman A, and Stier CT Jr. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 31: 451-458, 1998.
24. Rocha R, Chander P, Zuckerman A, and Stier CT Jr. Role of Mineralocorticoids in renal injury in stroke prone spontaneously hypertensive rats (Abstract). Hypertension 32: 598, 1998.
25. Rocha R, Chander PN, Zuckerman A, and Stier CT Jr. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 33: 232-237, 1999.
26. Rocha R, Stier CT Jr, Kifor I, Ochoa-Maya MR, Rennke H, Williams GH, and Adler GK. Aldosterone: A mediator of myocardial necrosis and renal injury. Endocrinology 141: 3871-3878, 2000.
27. Rollins BJ, Walz A, and Bagglioni M. Recombinant human MCP-1/JE induces chemotaxis, calcium flux, and the respiratory burst in human monocytes. Blood 78: 1112-1116, 1991.
28. Selye H. The general adaptation syndrome and the diseases of adaptation. J Clin Endocrinol Metab 6: 117-230, 1946.
29. Singh K, Balligand JL, Fischer TA, Smith TW, and Kelly RA. Glucocorticoids increase osteopontin expression in cardiac myocytes and microvascular endothelial cells. J Biol Chem 270: 28471-28478, 1995.
30. Takeda Y, Miyamori I, Inaba S, Furukawa K, Hatakeyama H, Yoneda T, Mabuchi H, and Takeda R. Vascular aldosterone in genetically hypertensive rats. Hypertension 29: 45-48, 1997.
31. Wang D, Yamamoto S, Hijiya N, Benveniste EN, and Gladson CL. Transcriptional regulation of the human osteopontin promoter: Functional analysis and DNA-protein interactions. Oncogene 19: 5801-5809, 2000.
32. Wong SC, Fukuchi M, Melnyk P, Rodger I, and Giaid A. Induction of cyclooxygenase-2 and activation of nuclear factor-κB in myocardium of patients with congestive heart failure. Circulation 98: 100-103, 1998.
33. Young MJ and Funder JW. The renin-angiotensin-aldosterone system in experimental mineralocorticoid-salt-induced cardiac fibrosis. Am J Physiol Endocrinol Metab 271: E883-E888, 1996.
34. Young W, Mahboubi K, Haider A, Li I, and Ferreri NR. Cyclooxygenase-2 is required for tumor necrosis factor-α- and angiotensin II-mediated proliferation of vascular smooth muscle cells. Circ Res 86: 906-914, 2000.
35. Zhou MY, Gomez-Sanchez CE, and Gomez-Sanchez EP. An alternatively spliced rat mineralocorticoid receptor mRNA causing truncation of the steroid binding domain. Mol Cell Endocrinol 159: 125-131, 2000.